Nature Communications (Nov 2020)
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
- Keito Okazaki,
- Hayato Anzawa,
- Zun Liu,
- Nao Ota,
- Hiroshi Kitamura,
- Yoshiaki Onodera,
- Md. Morshedul Alam,
- Daisuke Matsumaru,
- Takuma Suzuki,
- Fumiki Katsuoka,
- Shu Tadaka,
- Ikuko Motoike,
- Mika Watanabe,
- Kazuki Hayasaka,
- Akira Sakurada,
- Yoshinori Okada,
- Masayuki Yamamoto,
- Takashi Suzuki,
- Kengo Kinoshita,
- Hiroki Sekine,
- Hozumi Motohashi
Affiliations
- Keito Okazaki
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Hayato Anzawa
- Department of System Bioinformatics, Graduate School of Information Sciences, Tohoku University
- Zun Liu
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Nao Ota
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Hiroshi Kitamura
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Yoshiaki Onodera
- Department of Anatomic Pathology, Tohoku University Graduate School of Medicine
- Md. Morshedul Alam
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Daisuke Matsumaru
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Takuma Suzuki
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Fumiki Katsuoka
- Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University
- Shu Tadaka
- Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University
- Ikuko Motoike
- Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University
- Mika Watanabe
- Department of Pathology, Tohoku University Hospital
- Kazuki Hayasaka
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Akira Sakurada
- Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University
- Yoshinori Okada
- Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University
- Masayuki Yamamoto
- Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University
- Takashi Suzuki
- Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine
- Kengo Kinoshita
- Department of System Bioinformatics, Graduate School of Information Sciences, Tohoku University
- Hiroki Sekine
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- Hozumi Motohashi
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University
- DOI
- https://doi.org/10.1038/s41467-020-19593-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 19
Abstract
Aberrant activation of NRF2 in cancer cells contributes to tumorigenicity and therapeutic resistance. Here, the authors show that NRF2 cooperates with CEBPB and remodels enhancers to confer tumor-initiating activity on NRF2- activated non-small cell lung cancers.
